The CAMEO registry, an ongoing study to provide real-world data on KENGREAL® (cangrelor), has published interim results in the Journal of the American Heart Association.This analysis from CAMEO is the...
CARY, N.C., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the new publication of a post hoc analysis of the CHAMPION PHOENIX clinical trial that evaluated the timing, number and type of early cardiovascular events that occurred with treatment of KENGREAL® (cangrelor) compared to clopidogrel in patients undergoing PCI. The analysis is published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association, and can be accessed here. The overall trial results of CHAMPION PHOENIX showing a significant benefit in the primary endpoint and key secondary endpoint were previously published in the New England Journal of Medicine and can be accessed here.
Apotex's Generic Metformin HCl Receives Approval in the U.S.
Gland Pharma's Generic Cangrelor Receives Approval in the U.S.
MSN Laboratories, one of country’s leading, fully integrated research-based pharmaceutical organizations with expertise spanning across the domains of APIs, finished dosages and branded generics (prescription medicines), became the first company to launch the generic canreal injection (Cangrelor) in India.
CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of a cost-consequence analysis of KENGREAL® (cangrelor) in patients receiving percutaneous coronary intervention (PCI) in the online edition of the American Journal of Cardiovascular Drugs. KENGREAL is indicated as an adjunct to PCI to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the publication of a cost-consequence analysis of KENGREAL® (cangrelor) in patients receiving percutaneous coronary intervention (PCI) in the online edition of the American Journal of Cardiovascular Drugs. KENGREAL is indicated as an adjunct to PCI to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
FDA Confirms Paragraph IV Patent Challenge of Kengreal 204958 (Cangrelor) For Injection 50 mg/vial
Medicines` Kengrexal (cangrelor) Approved in Europe For ACS
The Medicines Company Kengreal Gets FDA Support After Previous Setbacks